{"filings":[{"id":833397,"accession_number":"0001664710-26-000034","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-06-03T20:01:21+00:00","items":["5.07"],"status":"ready","headline":"Keros Therapeutics announces stockholder votes at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Jean-Jacques Bienaimé and Charles Newton as directors with 10,093,559 and 14,716,598 votes for, respectively.","Ratified Deloitte & Touche LLP as independent auditor for FY 2026 (16,708,279 for, 783,953 against).","Advisory vote on executive compensation approved (14,273,625 for, 974,049 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":777716,"accession_number":"0001664710-26-000032","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-06-01T20:02:02+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO to present at Goldman Sachs healthcare conference June 8","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Jasbir Seehra will participate in fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference.","Presentation scheduled for Monday, June 8, 2026 at 4:00 p.m. Eastern time.","Live audio webcast available; replay accessible on Keros website for 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77922,"accession_number":"0001664710-26-000029","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-05-14T12:01:38+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros reports Q1 net loss $23.7M; Takeda plans Phase 3 for elritercept in myelofibrosis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.7M in Q1 2026 vs net income $148.5M in Q1 2025 due to prior-year Takeda license revenue.","R&D expenses fell 67% to $16.1M from $48.7M; transition of elritercept to Takeda and restructuring.","Cash $281.5M as of Mar 31, 2026; expected funding into first half 2028.","Takeda plans Phase 3 trial of elritercept for anemia in myelofibrosis, broadening beyond MDS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":32000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106973,"accession_number":"0001664710-26-000024","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros collaborates with Mass General on Phase 2 ALS trial of rinvatercept; presents new Phase 1 data at MDA Conf.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered agreement with Massachusetts General Hospital for Phase 2 ALS trial within HEALEY ALS MyMatch program.","Additional Phase 1 data presented at 2026 MDA Conference: rinvatercept generally well-tolerated with no serious adverse events.","Phase 1 data showed increased muscle mass, decreased fat mass, and increased bone mineral density in healthy volunteers.","Proteomic analysis confirmed target engagement and anti-fibrotic/anti-inflammatory effects consistent with activin inhibition.","Keros plans two Phase 2 trials: one in Duchenne muscular dystrophy (DMD) and one in ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106972,"accession_number":"0001664710-26-000021","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros Therapeutics updates corporate presentation; no material new disclosures in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished a corporate presentation dated March 2026 for investor meetings.","Presentation is available on Keros's website; no forward-looking statements or specific data excerpted.","No financial results, pipeline milestones, or guidance changes were disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106971,"accession_number":"0001664710-26-000017","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros Therapeutics reports Q4 net loss $23.5M, full-year net income $87.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $23.5M vs. $46.0M loss in Q4 2024; FY 2025 net income $87.0M vs. $187.4M loss in FY 2024.","Cash and equivalents $287.4M as of Dec 31, 2025, expected to fund operations into first half of 2028.","R&D expenses fell to $17.9M (Q4) and $129.6M (FY) due to transition of elritercept costs to Takeda.","Charles Newton appointed to board effective March 9, 2026; Carl Gordon steps down. Esther Cho promoted to Chief Legal Officer.","Phase 2 trial of rinvatercept for DMD expected to start in Q2 2026; ALS regulator engagement planned for H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106970,"accession_number":"0001664710-26-000008","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Keros Therapeutics appoints Charles Newton to Board; Carl Gordon resigns effective March 9, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl Gordon, Ph.D., resigned from the Board and Compensation Committee, effective March 9, 2026; no disagreement with the Company.","Charles Newton appointed as Class III director, effective March 9, 2026, and will serve on Compensation and Audit Committees.","Newton is former CFO of Lyell Immunopharma and has held senior roles at Bank of America, Credit Suisse, and Morgan Stanley.","Newton currently serves on the boards of Novavax, Inc. and Coherus Oncology, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106969,"accession_number":"0001664710-26-000005","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros Therapeutics CEO to present at three healthcare conferences in Feb-Mar 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb 25, 2026 at 11:20 a.m. ET (corporate presentation).","TD Cowen 46th Annual Health Care Conference on Mar 3, 2026 at 9:50 a.m. ET (fireside chat).","Leerink Partners Global Healthcare Conference on Mar 10, 2026 at 1:00 p.m. ET (fireside chat).","Archived replays available on Keros website for up to 90 days after each event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106968,"accession_number":"0001664710-26-000003","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros Therapeutics corporate presentation highlights Phase 2 data and cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 KER-050 in lower-risk MDS: 45% RBC transfusion independence at 24 weeks (ASH Dec 2025).","Phase 2 KER-012 in PAH met primary endpoint: 35m improvement in 6-min walk distance at 24 weeks.","Cash, equivalents and short-term investments of $367.4M as of Sep 30, 2025, funding operations into 2028.","Upcoming milestones: KER-050 higher-risk MDS data mid-2026; KER-012 HFpEF trial start H1 2026; KER-065 Phase 1 data H1 2026.","No new financing, leadership changes, or material agreements disclosed in the update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123306,"accession_number":"0001664710-25-000086","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros net loss narrows to $7.3M in Q3; cash runway into H1 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.3M in Q3 2025 versus $53.0M in Q3 2024, driven by Takeda license revenue.","R&D expenses fell to $19.5M from $49.2M after elritercept transition to Takeda.","Cash and equivalents $693.5M; board authorized $375M return to stockholders.","Takeda plans to initiate Phase 3 trial of elritercept in first-line myelodysplastic syndromes.","Keros expects to fund operations into H1 2028 after capital return."],"consensus_eps_estimate":-1.0679,"consensus_eps_actual":2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":243484000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123305,"accession_number":"0001104659-25-099512","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","2.02","8.01","5.02","7.01","9.01"],"status":"ready","headline":"Keros repurchases $181M of stock from ADAR1 & Pontifax at $17.75; plans $194M tender offer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to repurchase all shares held by ADAR1 (13.3%) and Pontifax (11.8%) at $17.75/share for ~$181M total.","Plans to commence tender offer by end of October 2025 for up to $194M of additional shares at $17.75/share.","Directors Tomer Kariv and Ran Nussbaum resigned from board; Jean-Jacques Bienaimé appointed Nominating Committee Chair.","Preliminary cash and cash equivalents as of Sept 30, 2025: ~$693.5M.","Will distribute 25% of any net proceeds from Takeda license agreement received by Dec 31, 2028 to stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139976,"accession_number":"0001664710-25-000081","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros reports KER-065 Phase 1 data: BMD improvements sustained to Day 141","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial in healthy males showed no dose-limiting toxicities or serious adverse events.","Whole body BMD improved at Day 85 and was sustained through Day 141 (three months post-last dose).","Lumbar spine BMD increased after three doses and remained elevated through Day 141.","Bone biomarker changes indicated increased formation and reduced resorption, consistent with tissue-level effects.","Data presented at ASBMR 2025 support potential in Duchenne muscular dystrophy and bone disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139975,"accession_number":"0001664710-25-000078","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO to present at Wells Fargo and H.C. Wainwright conferences","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Jasbir Seehra will participate in a fireside chat at Wells Fargo Healthcare Conference on Sept 4 at 2:15 p.m. ET.","He will also present at H.C. Wainwright 27th Annual Global Investment Conference on Sept 9 at 12:00 p.m. ET.","Archived replays will be available on Keros website for up to 90 days after each event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139974,"accession_number":"0001664710-25-000073","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros receives FDA Orphan Drug designation for KER-065 in Duchenne muscular dystrophy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug designation for KER-065, a TGF-ß family protein-targeting therapy for DMD.","Designation provides potential 7-year market exclusivity, tax credits, and fee waivers if approved.","KER-065 is advancing toward a Phase 2 clinical trial in patients with DMD, as stated by CEO.","DMD affects fewer than 200,000 people in the U.S., qualifying for Orphan Drug status.","Keros (KROS) is a clinical-stage biopharma focused on TGF-ß signaling disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139973,"accession_number":"0001664710-25-000071","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Keros discontinues cibotercept development, prioritizes KER-065; CEO becomes President, COO departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinuing all internal development of cibotercept (KER-012) after PAH trial termination.","Exclusively prioritizing KER-065 for Duchenne muscular dystrophy; Phase 2 expected Q1 2026.","CEO Jasbir Seehra adds President role effective Aug 18, 2025; steps down as Board Chair.","Jean-Jacques Bienaimé appointed Chair of the Board, effective Aug 18, 2025.","COO Christopher Rovaldi to depart Aug 18; Lorena Lerner promoted to CSO; SVP roles eliminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139972,"accession_number":"0001664710-25-000068","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros Q2 net loss narrows to $30.7M; Board plans $375M capital return to stockholders","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.7M in Q2 2025 improved from $45.3M in Q2 2024, driven by Takeda license revenue.","Cash and cash equivalents $690.2M at June 30, 2025, up from $559.9M at Dec 31, 2024.","Board approved return of $375M excess capital to stockholders; cash runway into H1 2028.","Lead asset KER-065 progressing toward Phase 2 trial in Duchenne muscular dystrophy starting Q1 2026.","R&D expenses $43.5M, G&A $14.5M for Q2 2025; both increased vs year-ago period."],"consensus_eps_estimate":-1.1545,"consensus_eps_actual":2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":229360000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139971,"accession_number":"0001664710-25-000062","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros doses first patient in Phase 3 RENEW trial of elritercept; $10M milestone from Takeda","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 3 RENEW trial of elritercept for adults with transfusion-dependent anemia with very low, low, or intermediate risk MDS.","Milestone payment of $10 million triggered from Takeda under global license agreement.","Keros received $200M upfront in Feb 2025; eligible for milestones exceeding $1.1B and tiered royalties.","RENEW is global, randomized, double-blind, placebo-controlled; primary endpoint is reduction in red blood cell transfusions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139970,"accession_number":"0001664710-25-000059","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Keros Therapeutics CMO Yung Chyung resigns effective Aug 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Yung H. Chyung, M.D. resigned effective August 1, 2025.","Resignation is voluntary and not due to any disagreement with the company.","Company has initiated a search for a new Chief Medical Officer.","Dr. Chyung served as CMO and member of the executive team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157595,"accession_number":"0001664710-25-000057","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Keros Therapeutics concludes strategic review, plans $375M capital return","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously approved $375M excess capital return to stockholders; structure and terms to be announced.","Strategic review included evaluation of sale, business combination, and continued investment; outreach to third parties and stockholders.","Company to continue development of lead candidate KER-065 for Duchenne muscular dystrophy.","2025 annual meeting results: all three director nominees elected, Deloitte & Touche ratified, executive compensation approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157594,"accession_number":"0001664710-25-000055","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO to speak at Goldman Sachs Healthcare Conference on June 9","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Jasbir Seehra to participate in a fireside chat at Goldman Sachs 46th Annual Global Healthcare Conference.","Presentation scheduled for June 9, 2025 at 9:20 a.m. Eastern time.","Live audio webcast available; archived replay on Keros website for up to 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157593,"accession_number":"0001664710-25-000052","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Keros ends PAH program, cuts 45% of staff, expects $17M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.","Workforce reduced ~45% to 85 employees; one-time severance charges of ~$3.2M in Q2 2025.","Annualized cost savings of ~$17M expected; restructuring substantially complete by Q4 2025.","Strategic alternatives review ongoing; preliminary update to be provided by June 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157592,"accession_number":"0001664710-25-000050","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros Therapeutics to Present at Bank of America 2025 Global Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jasbir Seehra to participate in fireside chat on May 13, 2025 at 8:00 p.m. Eastern time","Press release issued May 12, 2025 announcing the event via SEC Form 8-K","Live webcast available at bofa.veracast.com; archived replay on Keros website for 90 days"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157591,"accession_number":"0001664710-25-000045","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros Q1 net income $148.5M on Takeda license; cash $720.5M; KER-065 Phase 2 plan Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $148.5M vs net loss of $43.1M YoY; revenue driven by Takeda license agreement.","Research and development expenses $48.7M, up from $38.3M YoY, due to pipeline advancement.","Cash and cash equivalents $720.5M expected to fund operations into 2029.","Phase 1 KER-065 topline met objectives; plan to start Phase 2 in Q1 2026 after regulatory engagement.","Phase 2 TROPOS trial of cibotercept (KER-012) in PAH data expected Q2 2025; Board reviewing strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":3.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":211192000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157590,"accession_number":"0001664710-25-000038","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Keros Therapeutics agrees with Pontifax on director slate & standstill through 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement nominates Mary Ann Gray, Ran Nussbaum, and Alpna Seth for election at 2025 annual meeting.","Pontifax agrees to standstill until earlier of Dec 31, 2025 or 30 days before 2026 annual meeting deadline.","Parties agree to mutual non-disparagement obligations until the sunset date.","Letter agreement filed as Exhibit 10.1; resolves potential activist governance conflict."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157589,"accession_number":"0001664710-25-000033","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Keros Therapeutics adopts poison pill and launches strategic review including potential sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board formed Strategic Committee to evaluate strategic alternatives including sale or business combination.","Adopted limited-duration rights plan (10% threshold, 15% for passive institutional) expiring April 9, 2026.","Rights plan triggered by an individual investor that disclosed 11.2% ownership as of April 6, 2025.","Dividend of one right per common share for stockholders of record on April 24, 2025.","Goldman Sachs & Co. LLC engaged as financial advisor; Cooley LLP as legal counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175965,"accession_number":"0001664710-25-000029","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros announces positive Phase 1 results for KER-065; plans Phase 2 in DMD in Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KER-065 generally well-tolerated; no serious adverse events or dose-limiting toxicities reported.","Evidence of activin inhibition: increases in BSAP, adiponectin, and bone density; decreases in CTX, leptin, and fat mass.","Body composition changes included increased muscle mass and reduced fat mass consistent with activin inhibition.","Company expects to initiate Phase 2 trial in Duchenne muscular dystrophy in Q1 2026 after regulatory engagement.","Phase 1 data cut-off Feb 6, 2025; multiple ascending dose period through Day 85 completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175964,"accession_number":"0001664710-25-000025","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Keros Therapeutics amends bylaws to update director nomination procedures, universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Updated advance notice provisions for director nominations, including requirements under Rule 14a-19 and limiting nominees to board seats available.","Enhanced disclosure requirements for nominating stockholders and nominees, with obligation to update and supplement information.","Clarified procedures for stockholder meetings, including meeting place, adjournment, notices, conduct, and stockholder lists.","Conforming edits and other clarifying updates to improve consistency across bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175963,"accession_number":"0001664710-25-000022","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO to present at TD Cowen and Leerink healthcare conferences in March","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Jasbir Seehra to present at TD Cowen 45th Annual Healthcare Conference on March 3, 2025 at 9:50 a.m. ET.","CEO to present at Leerink Partners Global Healthcare Conference on March 10, 2025 at 1:40 p.m. ET.","Both presentations will be in fireside chat format with webcast links provided.","Archived replays available on Keros investor website for up to 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175962,"accession_number":"0001664710-25-000015","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros Therapeutics Q4 2024 net loss $46.0M; receives $200M Takeda upfront for elritercept","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.0M in Q4 2024 vs $40.2M in Q4 2023; full-year net loss $187.4M.","Revenue of $3.0M in Q4 2024 vs $0.1M in prior period, largely from Hansoh milestone.","Cash and equivalents $559.9M at Dec 31, 2024; plus $200M Takeda upfront payment received Feb 2025 extends runway into 2029.","Phase 1 data for KER-065 expected in Q1 2025; Phase 2 TROPOS trial data for cibotercept (KER-012) planned.","R&D expenses rose to $45.6M in Q4 2024, driven by elritercept Phase 3 and TROPOS trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175961,"accession_number":"0001664710-25-000010","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO Jasbir Seehra to present at Guggenheim SMID Cap Biotech Conference on Feb 6","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chair and CEO Jasbir Seehra will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference.","Presentation scheduled for Thursday, February 6, 2025, at 10:00 a.m. Eastern time.","Live webcast and 90-day replay available via Keros investor relations page."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175960,"accession_number":"0001664710-25-000008","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros-Takeda license for elritercept effective; $200M upfront payment triggered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Global license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept became effective Jan 16, 2025.","Upfront payment of $200.0 million from Takeda to Keros was triggered upon effectiveness.","Agreement was previously announced on Dec 3, 2024; effectiveness followed HSR waiting period expiration.","Elritercept is a clinical-stage therapy targeting TGF-ß family signaling disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175959,"accession_number":"0001664710-25-000005","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros halts entire Phase 2 PAH trial (all doses, placebo) on pericardial effusion safety","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntary halt of all dosing in TROPOS trial, including 1.5 mg/kg and placebo arms, due to new pericardial effusion adverse events.","Previously halted 3.0 mg/kg and 4.5 mg/kg arms on Dec 12, 2024; now entire study terminated early.","Patients to be monitored through end-of-trial visits; investigators and FDA notified.","Company still expects to present topline data from all treatment arms in Q2 2025.","CEO Jasbir Seehra cited patient safety as top priority; working with FDA and other regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175958,"accession_number":"0001664710-25-000002","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros Therapeutics updates corporate presentation for investor meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated January 2025 posted on company website and attached as Exhibit 99.1.","No specific financial or clinical data disclosed in the furnished exhibit excerpt.","Update is procedural for routine investor communications; no material news identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192881,"accession_number":"0001664710-24-000102","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros halts two high-dose arms of Phase 2 PAH trial after pericardial effusion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntarily halted dosing in 3.0 mg/kg and 4.5 mg/kg cibotercept arms in ongoing TROPOS trial.","Decision based on unanticipated pericardial effusion adverse events; safety review triggered.","1.5 mg/kg treatment arm continues dosing after DMC and internal risk-benefit assessment.","Topline data from all treatment arms still expected in Q2 2025; FDA and other regulators notified.","CEO Jasbir Seehra stated patient safety is top priority; Company investigating findings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192880,"accession_number":"0001664710-24-000099","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros reports elritercept Phase 2 data: 134.1 wk median TI in MDS; spleen reductions in MF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["55.2% (48/87) of mITT patients achieved overall erythroid response; median TI duration 134.1 weeks in lower-risk MDS.","31.4% (16/51) of high-transfusion-burden MDS patients achieved TI >=8 weeks; 50% of those had TI >=24 weeks.","In MF, 63.4% (26/41) of transfusion-dependent patients had reduced RBC burden; 24.4% achieved TI.","40% (8/20) of MF patients with baseline spleen >=450 cm³ had spleen volume reduction at week 24; 3 had >=35% reduction.","Elritercept generally well-tolerated; Phase 3 RENEW trial in MDS expected to begin enrollment soon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192879,"accession_number":"0001664710-24-000097","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Keros licenses elritercept to Takeda for $200M upfront; milestones up to $1.1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $200M; eligible for up to $370M in development/commercial milestones and $740M in sales milestones.","Tiered royalties on net sales in Territory (ex-China) from low double-digits to high teens, subject to reductions.","Elritercept in Phase 2 for MDS and myelofibrosis; Phase 3 RENEW trial for MDS to begin enrollment soon.","Keros expects upfront proceeds to extend cash runway into Q4 2028, supporting cibotercept and KER-065 programs.","Agreement effective subject to HSR Act clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192878,"accession_number":"0001664710-24-000094","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO to present at Piper Sandler and Evercore HealthConx conferences in December","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Jasbir Seehra will speak at Piper Sandler 36th Annual Healthcare Conference on Dec 3 at 10:30 a.m. ET.","CEO will also present at 7th Annual Evercore HealthConx Conference on Dec 4 at 3:00 p.m. ET.","Both presentations are fireside chat format with archived replays on Keros website for 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192877,"accession_number":"0001664710-24-000088","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros Q3 net loss $53M; cash $530.7M; Phase 2 PAH trial fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.0M in Q3 2024 vs $39.4M in Q3 2023; R&D expenses rose to $49.2M.","Cash and cash equivalents $530.7M as of Sep 30, 2024; ATM proceeds extend runway into Q3 2027.","Completed enrollment ahead of schedule in Phase 2 TROPOS trial (cibotercept) for pulmonary arterial hypertension.","Appointed Yung H. Chyung, M.D. as Chief Medical Officer effective Nov 1, 2024.","Expects clinical data updates from three assets over next nine months."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192876,"accession_number":"0001664710-24-000086","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO to present at Guggenheim Healthcare Innovation Conference on Nov 13","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Jasbir Seehra will speak at the Guggenheim Healthcare Innovation Conference on November 13, 2024 at 3:30 p.m. ET.","A live webcast will be available at wsw.com/webcast/guggen/kros/1967811; replay for 90 days on ir.kerostx.com.","No financial results or material business updates were disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192875,"accession_number":"0001664710-24-000081","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Keros Therapeutics appoints Yung H. Chyung as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Chyung appointed Chief Medical Officer effective November 1, 2024, succeeding Simon Cooper.","He will receive an annual base salary of $510,000 and a target bonus of 40% of base salary.","Eligible for a stock option to purchase 110,000 shares vesting over four years.","Previously Executive VP and CMO at Tourmaline Bio (2022-2024) and CMO at Scholar Rock (2016-2022).","Company press release issued October 16, 2024, announcing the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209285,"accession_number":"0001664710-24-000078","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Keros completes Phase 2 PAH trial TROPOS enrollment with 113 patients; topline Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment of TROPOS Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.","Enrolled 113 patients, exceeding the initial target of 90 patients.","Topline data expected to be presented in the second quarter of 2025.","Trial evaluates cibotercept in combination with background therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209284,"accession_number":"0001664710-24-000075","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros closes screening for Phase 2 TROPOS trial in PAH; expects topline data in Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 TROPOS trial of cibotercept (KER-012) for PAH has closed screening.","Company expects to complete enrollment by end of September 2024.","Topline data now expected in Q2 2025, earlier than previously anticipated.","CEO Jasbir Seehra cited strong demand and rapid enrollment as catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209283,"accession_number":"0001664710-24-000072","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros CEO to present at three healthcare conferences in September 2024","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Jasbir Seehra will participate in fireside chats at Morgan Stanley, Wells Fargo, and Cantor conferences.","Morgan Stanley 22nd Annual Global Healthcare Conference on Sept 4, 2024 at 4:05 pm ET.","2024 Wells Fargo Healthcare Conference on Sept 5, 2024 at 10:15 am ET.","2024 Cantor Global Healthcare Conference on Sept 19, 2024 at 8:35 am ET.","Webcast replays will be available on Keros' website for 90 days post-event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209282,"accession_number":"0001664710-24-000069","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros updates corporate deck; no material facts discernible from truncated exhibit","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Keros Therapeutics furnished an updated corporate presentation for investor meetings under Item 7.01.","The attached Exhibit 99.1 text is incomplete in the filing, preventing extraction of specific updates.","No financial results, clinical milestones, or guidance changes can be confirmed from available text.","The filing is a routine practice and does not indicate any material new development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209281,"accession_number":"0001664710-24-000067","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Keros Therapeutics reports Q2 2024 net loss of $45.3M; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $45.3M in Q2 2024, up from $37.5M in Q2 2023 due to increased R&D spend.","R&D expenses $40.5M (Q2 2024) vs $32.5M (Q2 2023); G&A $10.0M vs $8.8M.","Cash and equivalents $405.9M as of June 30, 2024, expected to fund operations into 2027.","Elritercept (KER-050) positive regulatory/data updates; cibotercept (KER-012) Phase 2 PAH enrollment to complete Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227243,"accession_number":"0001664710-24-000059","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros Therapeutics files prospectus supplement for up to $350M at-the-market stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on June 17, 2024 to sell up to $350 million of common stock via ATM program.","Leerink Partners acts as sales agent, earning a commission of up to 3.0% of gross proceeds.","Sales may be made directly on the Nasdaq Global Market; company not obligated to sell any shares.","Original sales agreement dated May 3, 2021; shelf registration statement effective May 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227242,"accession_number":"0001664710-24-000058","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Keros CEO Seehra becomes Chair; Rovaldi promoted to President effective July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jasbir Seehra appointed Chair of Board, effective July 1, 2024, succeeding Carl Gordon who remains director.","Christopher Rovaldi promoted to President in addition to COO, effective July 1, 2024, replacing Seehra as President.","Jean-Jacques Bienaimé appointed Lead Independent Director, effective July 1, with a new $25,000 annual retainer.","Leadership changes come as Keros prepares for first registrational Phase 3 trial of elritercept (KER-050)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227241,"accession_number":"0001664710-24-000055","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros reports durable transfusion independence in Phase 2 MDS trial; plans registrational Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall erythroid response 55.6% (45/81) in modified ITT patients; 41.3% (26/63) of TI-evaluable achieved ≥8-week transfusion independence.","Median duration of TI not reached; 42.3% (11/26) of TI responders had responses >1 year, all ongoing as of April 3, 2024.","In MF Phase 2, 60.6% (20/33) of transfusion-dependent patients had reduced transfusion burden; 52.9% (9/17) with large spleens had volume reductions at Week 24.","Preclinical MF model data shows elritercept promotes erythropoiesis, mitigates anemia, and improves muscle mass/function.","Company plans to initiate a registrational Phase 3 trial in lower-risk MDS following positive FDA feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227240,"accession_number":"0001664710-24-000050","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Keros receives positive FDA feedback on KER-050 MDS program; Phase 3 design aligned","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA feedback resulted in general alignment on design and endpoints for proposed pivotal Phase 3 trial of KER-050 (elritercept) in MDS.","Company to host corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. ET.","Expects to complete enrollment of Phase 2 TROPOS trial evaluating KER-012 (cibotercept) in PAH in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227239,"accession_number":"0001664710-24-000047","cik":1664710,"company_name":"Keros Therapeutics, Inc.","ticker":"KROS","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Keros Therapeutics CEO to present at Goldman Sachs Healthcare Conference June 10","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Jasbir S. Seehra, Ph.D., to participate in fireside chat at Goldman Sachs 45th Annual Healthcare Conference.","Presentation scheduled for June 10, 2024 at 2:40 p.m. Eastern time.","Live webcast available; archived replay accessible for 90 days on Keros website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":222856101.07692304,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-03T23:59:59+00:00|227239"}